In the EMPOWER-Lung 01 study (NCT03088540) [9], cemiplimab monotherapy was found to improve the progression-free survival (PFS) of patients with advanced non-small cell lung cancer (NSCLC) who had PD-L1 ≥ 50 % (median PFS: 8.2 months vs. 5.7 months; HR 0.54, 95 % CI: [0.43, 0.68]). This evidence concerns the gene CD274 and non-small cell lung carcinoma.